338 research outputs found
2019 Swinburne Annual Barak Wonga Oration
No full text2019 Swinburne Annual Barak Wonga Oration - My life journey in Aboriginal Affairs. Swinburne University of Technology and the Moondani Toombadool Centre were proud to have Dr Jackie Huggins AM deliver the 2019 Annual Barak Wonga Oration. Dr Huggins discusses her extraordinary journey in Aboriginal Affairs as an author, academic, historian and Aboriginal rights activist, including her work with National Congress of Australia’s First Peoples, Reconciliation Australia, the Inquiry into the Separation of Aboriginal Children, the Council for Aboriginal Reconciliation, and the Australian Institute for Aboriginal and Torres Strait Islander Studies. Dr Huggins discusses key areas of Indigenous rights and self-determination, the milestones she has seen in her lifetime, including the Mabo and Wik High Court decisions, the reconciliation movement, native title, Indigenous education, and gender representation, and the successes, disappointments and challenges.
Lecture held at the Advanced Manufacturing and Design Centre, Level 3 Lecture Theatre on 1 August 2019
Idan Ben-Barak: Cook Prize 2024, Silver Medal Acceptance Speech.
No full textAuthor Idan Ben-Barak gives an acceptance speech for We Go Way Back (Roaring Brook Press)https://educate.bankstreet.edu/cook/1010/thumbnail.jp
Dr Jackie Huggins AM, 2019
No full textLeft to right: Professor Andrew Gunston, Professor Linda Kristjanson, Uncle Colin Hunter Junior and Dr Jackie Huggins.
Author, historian, academic and Aboriginal rights activist, Dr Jackie Huggins AM has been appointed as Swinburne’s inaugural Vice-Chancellor's Fellow for Indigenous Leadership.
The appointment was announced as part of Swinburne's annual Barak-Wonga Oration, which was delivered by Dr Huggins. The oration is named in honour of two significant Aboriginal leaders, William Barak and Simon Wonga, and is a key element of Swinburne’s Reconciliation Action Plan (RAP).
Dr Huggins has previously worked with Swinburne, making a substantial contribution to its inaugural National RAP Conference in 2018.
In her role as Vice-Chancellor's Fellow for Indigenous Leadership, Dr Huggins will continue to contribute to Swinburne reconciliation activities.
Photograph originally appeared in the Media Centre Release, 'Dr Jackie Huggins AM named VC’s Fellow for Indigenous Leadership' on Friday 02 August 2019
Partition, Politics, and the Quest for Bengali Identity: A Case of Barak Valley in South Assam
No full textThis article is reproduced here with permission from the author and may be found online at http://www.mcrg.ac.in/rw%20files/RW61_62/RW61_62.pdf.Prior to independence, Barak Valley was a part of Surma Valley. When Sylhet and Cachar, two Bengali speaking districts of the Bengal Presidency, were separated and combined to form Assam in 1874, Surma Valley administrative division was created. Until Sylhet’s secession to East Pakistan in 1947 Cachar district remained a part of Surma Valley. After Sylhet, Cachar district became the lone Bengali stronghold in Assam. In late twentieth century, Barak Valley became the name of Cachar district which included remnants of erstwhile Sylhet. Historically, Barak Valley has gone through partition twice- once in 1874 when it was severed from Bengal and again in 1947 when Sylhet voted to secede. In post-independent Assam, Barak Valley turned into an alien land. Subsequent actions of the leadership have significantly impacted the socio-political life and strengthened the sense of isolation of Barak Valley. The present study is intended to comprehend how Barak Valley has struggled to preserve its identity despite going through a serious existential crisis
Supplementary Figures 3 and 4 -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
No full textSupplemental material, Supplementary Figures 3 and 4 for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p
Supplementary Figure 1 bottom panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
No full textSupplemental material, Supplementary Figure 1 bottom panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p
Supplementary Tables -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
No full textSupplemental material, Supplementary Tables for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p
Supplementary Figure 2 middle panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
No full textSupplemental material, Supplementary Figure 2 middle panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p
Supplementary Figure 2 bottom panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
No full textSupplemental material, Supplementary Figure 2 bottom panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p
Supplementary Figure 1 top panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
No full textSupplemental material, Supplementary Figure 1 top panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p
- …
